PE2/PE3 mRNA (Cap1, m1Ψ)

Prime editing (PE) systems minimally consist of two components: a programmable DNA nickase fused to an engineered reverse transcriptase and a pegRNA. The PE2/PE3 mRNA sequence was from publication: Nelson, et al. Nat Biotechnology, 2022; 40: 402-410. This mRNA is capped with Cap1 structure with high capping efficiency. It has 100% substituted with N1-methyl-pseudoUridine for enhanced expression and reduced immunogenicity. The mRNA has a 100A tail in its sequence, mimics a mature mRNA.

产品编号	RP-A00044
规格	0.1 mg 0.2 mg 1 mg 大单询价
数量
价格	￥1000


联系我们

Description

Prime editing (PE) systems minimally consist of two components: a programmable DNA nickase fused to an engineered reverse transcriptase and a pegRNA. The PE2/PE3 mRNA sequence was from publication: Nelson, et al. Nat Biotechnology, 2022; 40: 402-410.

This mRNA features:
- A Cap 1 structure with high capping efficiency
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response
- GenScript’s patented UTR to enhance translation
- A 100A poly(A) tail to mimic natural mature mRNA

产品属性

Form	Liquid
Concentration	1mg/mL
Full mRNA length	6652nt
Full mRNA Molecular Weight	2167186
Storage buffer	1mM Sodium citrate, pH6.5
Storage condition	Store at -20°C for short term (<3 months), store at -80°C for long term.

质控参数

Appearance	Clear and free of foreign particles
RNA Length	Expected size band detected
RNA Content	Target ± 5%
Integrity	≥ 75%
OD260/OD280	1.70 ~ 2.30
Capping Efficiency	≥ 90%
Endotoxin	< 10 EU/mg
pH	Target ± 0.5

应用指导

Transfect a total of 2 µg of PE2/PE3 mRNA and pegRNA per well, using a transfection reagent, electroporation, or LNP encapsulation in a 24-well plate (~2 × 10⁵ cells/well). Assess genome editing efficiency 48-72 hours post-transfection via sequencing.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.